Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B
Top Cited Papers
Open Access
- 1 June 2002
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 35 (6), 1522-1527
- https://doi.org/10.1053/jhep.2002.33638
Abstract
During the course of chronic hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) seroconversion to its antibody (anti‐HBe) often coincides with normalization of liver biochemical test and clinical remission, but data regarding long‐term outcome after spontaneous seroconversion are still scarce. Excluding patients with other virus(es) concurrent infection, 283 patients with chronic HBV infection were followed up for at least 1 year after spontaneous HBeAg seroconversion to anti‐HBe. Follow‐up studies included clinical, biochemical, and virologic evaluation and hepatocellular carcinoma (HCC) screening with ultrasonography and α‐fetoprotein assay. During a median follow‐up period of 8.6 years (range, 1 to 18.4 years) after HBeAg seroconversion in 283 patients, 189 (66.8%) showed sustained remission, whereas the remaining 94 (33.2%) experienced alanine aminotransferase (ALT) elevation over twice the upper limit of normal: 12 (4.2%) associated with HBeAg reversion, 68 (24%) with detectable serum HBV DNA but HBeAg negative, and 14 (4.9%) of undetermined causes. Of the 269 patients without evidence of cirrhosis at the time of HBeAg seroconversion, 21 (7.8%) developed cirrhosis with a cumulative incidence and relative risk significantly higher in patients developing active hepatitis than in patients with sustained remission (P < .05). HCC developed in 6 (2.2%) of the 283 patients, also with a significantly higher cumulative incidence in patients developing active hepatitis after HBeAg seroconversion (P < .005). In conclusion, the results suggest that spontaneous HBeAg seroconversion confers favorable long‐term outcomes. However, active hepatitis still may develop and lead to cirrhosis and HCC.Keywords
Funding Information
- Chang Gung Medical Research Fund (CMRP800)
This publication has 23 references indexed in Scilit:
- Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infectionHepatology, 1999
- Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis BHepatology, 1999
- The long‐term effect of treatment with interferon‐α2a in chronic hepatitis BJournal of Viral Hepatitis, 1998
- Treatment of Chronic Hepatitis B InfectionNew England Journal of Medicine, 1998
- Long-term follow-up of patients with chronic hepatitis B treated with interferon alfaGastroenterology, 1997
- Long-Term Follow-up of HBeAg-Positive Patients Treated with Interferon Alfa for Chronic Hepatitis BNew England Journal of Medicine, 1996
- Long-term follow-up of chronic hepatitis B patients treated with interferon alfaGastroenterology, 1993
- Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective studyHepatology, 1991
- Natural history of chronic hepatitis B virus infection in taiwan: Studies of hepatitis B virus DNA in serumHepatology, 1985
- Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B HepatitisAnnals of Internal Medicine, 1981